Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Amy V. Kapp"'
Autor:
Erika Hamilton, Mafalda Oliveira, Andrés Cervantes, Amy V. Kapp, Jennifer L. Schutzman, Nicholas C. Turner, Naoki Kotani, Zachary William Neil Veitch, Ian E. Krop, Dejan Juric, Antoine Italiano, Stephanie Royer-Joo, Komal Jhaveri, Philippe L. Bedard, Anjali Vaze, Peter Schmid, Katie Hutchinson, Kevin Kalinsky, Leslie J. Dickmann, Jill Fredrickson, Andrea Varga, Valentina Gambardella, Cristina Saura
Publikováno v:
Cancer Research. 80:OT1-08
Background: Activating mutations in PIK3CA, encoding the p110α subunit of phosphatidylinositol 3-kinase (PI3K), are highly prevalent in breast cancer and solid tumor malignancies. GDC-0077 is a potent p110α-selective inhibitor with a novel mechanis
Autor:
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga, Keun Seok Lee, Hwei-Chung Wang, Antoinette Tan, Joo Hyuk Sohn, Michelino De Laurentiis, Laura Garcia Estevez, Chiun-Sheng Huang, Gilles Romieu, Michel Velez, Rafael Villanueva, Pier Franco Conte, Shaker Dakhil, Marc Debled, Antonio Gonzalez Martin, Sara Hurvitz, Jee Hyun Kim, Christelle Levy, Pedro Sanchez Rovira, Jae Hong Seo, Vicente Valero, Gregory Vidal, Andrea Wong, Mary Ann K Allison, Robert Figlin, David Chan, Shin-Cheh Chen, Yen-Hsun Chen, Melody Cobleigh, Filippo De Braud, Luc Dirix, Vincent Hansen, Anne Hardy Bessard, Nicholas Iannotti, Steven Isakoff, William Lawler, Alvaro Montaño, Mohamad Salkini, Leonard Seigel
Publikováno v:
The Lancet. Oncology, vol 18, iss 10
Summary Background The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23bb66843d8ecfd467caeec1baf17b8a
https://escholarship.org/uc/item/7z70q2hf
https://escholarship.org/uc/item/7z70q2hf
Autor:
Begoña Bermejo, Isabel Calvo, Miguel Gil, José Baselga, José Luis Passos Coelho, Debra A. Patt, Eva Ciruelos, Amy V. Kapp, Daniel J. Maslyar, Wai Y. Chan, Mafalda Oliveira, Lorena de la Peña, Stina M. Singel, Cristina Saura, Steven J. Isakoff, Jay Andersen, Matthew Wongchenko
Publikováno v:
Cancer Research. 78:CT041-CT041
Purpose: This hypothesis-generating trial evaluated neoadjuvant IPAT + PAC for eTNBC. Methods: Patients (pts) with eTNBC, T ≥1.5 cm and N0-2 were randomized 1:1 to receive 12 wks of weekly PAC 80 mg/m² + either IPAT 400 mg or PBO d1-21 q28d before
Autor:
José Baselga, Wai Y. Chan, Debra A. Patt, Eva Ciruelos, Miguel Gil, Amy V. Kapp, Lorena de la Peña, Jay Andersen, José Luís Passos-Coelho, Julie Gottlieb Fisher, Daniel J. Maslyar, Mafalda Oliveira, Steven Gendreau, Isabel Calvo, Stina M. Singel, Serafin Morales Murillo, Cristina Saura, Steven J. Isakoff
Publikováno v:
Journal of Clinical Oncology. 34:TPS1105-TPS1105
TPS1105Background: TNBC often exhibits activation of PI3K/Akt signaling, associated with loss of PTEN expression, low INPP4B expression, PI3K/Akt mutations, or PI3K/AKT3 amplification. Inhibition of the PI3K/Akt pathway may lead to radiosensitization
Autor:
Stefanie S. Jeffrey, Dong Young Noh, Robert Tibshirani, Ida R. K. Bukholm, Anita Langerød, Amy V. Kapp, Anne Lise Børresen-Dale, Patrick O. Brown, Wonshik Han, Monica Nicolau
Publikováno v:
BMC Genomics, Vol 7, Iss 1, p 231 (2006)
BMC Genomics
BMC Genomics
Background Previous studies demonstrated breast cancer tumor tissue samples could be classified into different subtypes based upon DNA microarray profiles. The most recent study presented evidence for the existence of five different subtypes: normal
Autor:
Amy V. Kapp
Publikováno v:
Biostatistics; Jan2007, Vol. 8 Issue 1, p9-31, 23p